Aaron Lipson comments on the compliance risks posed by prediction markets tied to clinical drug trials, including potential insider trading and manipulation concerns. 

Third-party coverage: 
'A Moral Hazard': Kalshi Drug Trial Bets Spark Ethical Qualms